-
Strategies - Hip Implant Grinding
Time of Update: 2022-04-17
To achieve this, ANCA has developed a new process on its MX7 Linear grinder that includes a series of grinding, lapping and final polishing steps, resulting in femoral balls with a surface finish of less than 0.
-
The biomedical sector is trending strongly, with two stocks up more than 10%
Time of Update: 2022-04-16
As of the close of January 17, Nuohui Health rose nearly 34%, and the current total market value reached 13.
-
Hong Kong stock health care sector changes, Superstar Medical Holdings rose more than 6%
Time of Update: 2022-04-16
Qiming Medical-B2021 interim report shows that the company's cumulative net profit for the year was -136 million Hong Kong dollars, a year-on-year increase of -159.
-
Sought after by funds, the Chinese medicine sector gave birth to 3 bull stocks that doubled
Time of Update: 2022-04-16
According to the data, Longjin Pharmaceutical is a pharmaceutical company engaged in the research and development, production and sales of modern traditional Chinese medicine and characteristic chemical generic drugs .
-
The "Big White Horse" has fallen by the limit for three consecutive days, and the competition pattern of the growth hormone market may be rewritten
Time of Update: 2022-04-16
239 billion yuan; the net profit attributable to the parent company increased by 39% year-on-year to 3.
According to data from Oriental Fortune Choice, as of January 19, the average increase in the net value of 197 pharmaceutical manufacturing themed funds in the past year was -14.
-
Another new pharmaceutical stock opened and broke, but the R&D strength should not be underestimated
Time of Update: 2022-04-16
The global ADC drug market is huge and is expected to reach US$16.
4 billion by 2026, of which the new Nectin-4 ADC drug Padceve is expected to reach US$3.
6MW3211 is the first dual-antibody new drug developed by Maiwei Bio .
-
7th CHS 7th China Health Industry Upgrading Summit Theme Release: Two-way Innovation
Time of Update: 2022-04-16
As the 7th China Health Industry Upgrade Summit is about to be held, Yiou Health concluded that the development of the medical and health industry is showing a trend of "two-way innovation", "doctors and patients, inside and outside the hospital, technology and clinical, reality".
-
The traditional Chinese medicine sector changed again, and many stocks rose by the daily limit
Time of Update: 2022-04-16
[Pharmaceutical Network Pharmaceutical Stock Market] On January 5th, the traditional Chinese medicine sector changed again.
Sinolink Securities also pointed out that with the promotion of favorable policies for many years, the traditional Chinese medicine industry has ushered in new opportunities .
-
Since 2022, these pharmaceutical stocks have increased significantly
Time of Update: 2022-04-16
Data shows that in 2019, Asia Pacific Pharmaceuticals lost more than 2 billion yuan; in 2020, its net profit increased by 101.
It is reported that the continuous daily limit of Kaikai Industrial's share price is closely related to recent market rumors that its wholly-owned subsidiary Shanghai Leiyunshang Pharmaceutical West Co.
-
Next week, another new pharmaceutical stock will be subscribed for
Time of Update: 2022-04-16
Among them, the number of subscriptions for the special asset management plan established by the company's senior management and core employees participating in this strategic placement shall not exceed 10% of the number of this issuance, that is, no more than 4,001,000 shares, and the subscription amount shall not exceed 252 million yuan; The number of follow-up investments by related subsidiaries is expected to be no more than 5% of the number of this offering .
-
The pharmaceutical sector is still hot, and this stock has a daily limit of 16 times in the past year
Time of Update: 2022-04-16
[Pharmaceutical Network Pharmaceutical Stock Market] Under the catalysis of relevant good news, pharmaceutical stocks have set off a daily limit wave again . On January 19, the pharmaceutical sect
-
Today's pharmaceutical sector has a strong trend: nearly 10 stocks have daily limit, and one pharmaceutical company has three consecutive boards
Time of Update: 2022-04-16
[Pharmaceutical Network Pharmaceutical Stock Market] On January 10, 2022, the pharmaceutical sector had a strong intraday trend, including Yabao Pharmaceutical, Zhongsheng Pharmaceutical, Asia Pacific Pharmaceutical, Xintian Pharmaceutical, Shapuaisi, Huashen Technology, Guizhou San Nearly 10 stocks, including Lili, Sialon Pharmaceutical, and Teyi Pharmaceutical, were trading at their daily limit .
-
The traditional Chinese medicine sector reappears!
Time of Update: 2022-04-16
According to the third quarterly report of 2021, the company achieved a net profit of 128 million yuan from January to September, a year-on-year increase of 26.
5727 million yuan from January to September, a year-on-year increase of 187.
-
Anxu Bio, Rejing Bio and other pharmaceutical stocks rose more than 50% in the month
Time of Update: 2022-04-16
According to the data, Anxu Bio is a biopharmaceutical enterprise integrating R&D, production and sales of in vitro diagnostic reagents, POCT instruments and biological raw materials.
According to the data, Rejing Bio is a biological high-tech enterprise engaged in the research, development, production and sales of in vitro diagnostic reagents and instruments.
-
This pharmaceutical stock is "bull"!
Time of Update: 2022-04-16
Looking back at 2021, the overall performance of the pharmaceutical sector in the A-share market is weak, and the stock prices of pharmaceutical giants such as Hengrui Medicine cannot avoid a relatively large adjustment .
-
Cell gene therapy may take over biopharmaceuticals in the future, bringing new growth points to the pharmaceutical machinery industry
Time of Update: 2022-04-15
[Pharmaceutical Network Market Analysis] In recent years, with the rapid development of biopharmaceutical technology, the continuous increase in R&D investment of pharmaceutical companies, and the support of a series of favorable policies, superimposed on the impact of the epidemic, China's biopharmaceutical industry has developed rapidly.
-
my country has entered a critical period of pharmaceutical innovation-driven transformation, and basic research is the source
Time of Update: 2022-04-15
Facing the future, my country needs to continuously promote the innovation of the pharmaceutical industry, such as improving the research and development of original and high clinical value products and the strategy of going overseas.
-
Under the continuous transformation and upgrading of the pharmaceutical industry, personnel changes will become more frequent
Time of Update: 2022-04-15
In addition to AstraZeneca, many multinational pharmaceutical companies have also undergone major personnel adjustments this year: for example, the head of the Novartis Oncology Hematology Division resigned; the position of the head of the Takeda Oncology Division was finally settled after 2 months of vacancy ; Fresenius Kabi China changed its chief financial officer; Abbott's global vice president resigned, etc.
-
Two more pharmaceutical companies have reviewed it, and the market war for oral hypoglycemic drugs is intensifying
Time of Update: 2022-04-15
But at the same time, with the increased investment in research and development of enterprises, accelerated drug approval and review, and the support of capital, news of the listing of hypoglycemic drugs in the domestic market has continued to spread in recent years .
-
Chinese medicine presents a new development pattern, how to grasp the main line?
Time of Update: 2022-04-15
For example, Ping An Securities looks at opportunities in the TCM industry from five main lines, including innovative TCM drugs, branded OTC TCM, TCM formula granules, TCM injections, and TCM medical services .
